Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Lymphocytic, Chronic, B-Cell | 232 | 2024 | 1642 | 26.630 |
Why?
|
Lymphocytosis | 24 | 2023 | 121 | 8.030 |
Why?
|
Receptors, Antigen, B-Cell | 37 | 2023 | 547 | 4.300 |
Why?
|
B-Lymphocytes | 59 | 2023 | 4794 | 4.220 |
Why?
|
Pyrazoles | 27 | 2024 | 2029 | 3.320 |
Why?
|
Pyrimidines | 30 | 2025 | 3048 | 3.080 |
Why?
|
Adenine | 36 | 2024 | 995 | 2.940 |
Why?
|
Piperidines | 43 | 2024 | 1667 | 2.450 |
Why?
|
Genes, Immunoglobulin | 13 | 2024 | 286 | 2.110 |
Why?
|
Immunoglobulin Heavy Chains | 30 | 2024 | 648 | 1.880 |
Why?
|
Pyrazines | 15 | 2024 | 1206 | 1.870 |
Why?
|
Benzamides | 14 | 2024 | 1387 | 1.730 |
Why?
|
Immunoglobulin Variable Region | 24 | 2024 | 420 | 1.520 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 10 | 2022 | 180 | 1.380 |
Why?
|
Protein Kinase Inhibitors | 24 | 2025 | 5707 | 1.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 36 | 2024 | 11886 | 1.270 |
Why?
|
Toll-Like Receptors | 11 | 2023 | 582 | 1.220 |
Why?
|
Complementarity Determining Regions | 10 | 2020 | 154 | 1.150 |
Why?
|
Antineoplastic Agents | 34 | 2025 | 13698 | 1.100 |
Why?
|
Neoplasm, Residual | 9 | 2022 | 1019 | 1.090 |
Why?
|
Lymphoma, Follicular | 7 | 2022 | 460 | 1.090 |
Why?
|
Hematologic Neoplasms | 8 | 2023 | 1907 | 1.080 |
Why?
|
Lymphoma, B-Cell | 13 | 2025 | 945 | 1.050 |
Why?
|
Quinazolinones | 11 | 2022 | 219 | 1.040 |
Why?
|
Lymphoma, Mantle-Cell | 8 | 2022 | 240 | 1.020 |
Why?
|
Lymphocyte Count | 14 | 2021 | 794 | 1.010 |
Why?
|
Gene Expression Regulation, Leukemic | 17 | 2021 | 658 | 1.000 |
Why?
|
I-kappa B Proteins | 2 | 2024 | 210 | 1.000 |
Why?
|
Tumor Suppressor Protein p53 | 14 | 2024 | 2960 | 1.000 |
Why?
|
Precancerous Conditions | 5 | 2023 | 985 | 0.980 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2016 | 696 | 0.960 |
Why?
|
Purines | 13 | 2022 | 615 | 0.950 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 10 | 2015 | 91 | 0.920 |
Why?
|
Lymphoma | 6 | 2023 | 1900 | 0.900 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 16 | 2021 | 103 | 0.890 |
Why?
|
Chromosomes, Human, Pair 17 | 4 | 2020 | 419 | 0.880 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 179 | 0.870 |
Why?
|
Antigens, Neoplasm | 6 | 2020 | 2001 | 0.850 |
Why?
|
Leukemia, B-Cell | 5 | 2025 | 86 | 0.830 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 4 | 2021 | 58 | 0.810 |
Why?
|
Splenic Neoplasms | 6 | 2022 | 97 | 0.800 |
Why?
|
Immunogenetics | 7 | 2018 | 62 | 0.800 |
Why?
|
Humans | 279 | 2025 | 768970 | 0.800 |
Why?
|
Chlorambucil | 6 | 2022 | 42 | 0.780 |
Why?
|
Chromosome Deletion | 6 | 2020 | 1390 | 0.770 |
Why?
|
Immunophenotyping | 18 | 2022 | 1866 | 0.730 |
Why?
|
Immunoglobulins | 9 | 2022 | 855 | 0.710 |
Why?
|
Mutation | 39 | 2024 | 30266 | 0.710 |
Why?
|
Vidarabine | 7 | 2020 | 337 | 0.700 |
Why?
|
NF-kappa B | 5 | 2024 | 2492 | 0.680 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2020 | 827 | 0.660 |
Why?
|
Prognosis | 38 | 2022 | 30046 | 0.580 |
Why?
|
Sequence Analysis, Protein | 1 | 2018 | 265 | 0.570 |
Why?
|
Chemokines, CC | 4 | 2003 | 286 | 0.550 |
Why?
|
Chromosome Aberrations | 8 | 2022 | 1780 | 0.550 |
Why?
|
Pyridinium Compounds | 1 | 2017 | 81 | 0.550 |
Why?
|
Aged, 80 and over | 51 | 2025 | 59739 | 0.550 |
Why?
|
Aged | 87 | 2025 | 171786 | 0.520 |
Why?
|
Hedgehogs | 1 | 2015 | 5 | 0.510 |
Why?
|
Clonal Anergy | 3 | 2016 | 169 | 0.510 |
Why?
|
High-Throughput Nucleotide Sequencing | 12 | 2024 | 3671 | 0.510 |
Why?
|
Tumor Microenvironment | 17 | 2024 | 3952 | 0.460 |
Why?
|
Apoptosis | 16 | 2024 | 9527 | 0.460 |
Why?
|
Drug Resistance, Neoplasm | 14 | 2025 | 5342 | 0.460 |
Why?
|
Hematology | 2 | 2020 | 243 | 0.440 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 283 | 0.440 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2022 | 9442 | 0.430 |
Why?
|
Antibodies, Monoclonal | 7 | 2018 | 9264 | 0.420 |
Why?
|
Cancer Vaccines | 1 | 2020 | 1043 | 0.420 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2019 | 8664 | 0.410 |
Why?
|
Multiple Myeloma | 5 | 2023 | 5196 | 0.410 |
Why?
|
Lipoproteins, HDL | 1 | 2017 | 682 | 0.400 |
Why?
|
Lectins | 1 | 2014 | 490 | 0.390 |
Why?
|
Male | 101 | 2025 | 365203 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2016 | 1408 | 0.390 |
Why?
|
Flow Cytometry | 12 | 2019 | 5906 | 0.380 |
Why?
|
Clone Cells | 9 | 2013 | 1670 | 0.380 |
Why?
|
Sulfonamides | 7 | 2023 | 1981 | 0.380 |
Why?
|
Female | 100 | 2025 | 397515 | 0.370 |
Why?
|
T-Lymphocytes | 14 | 2023 | 10276 | 0.370 |
Why?
|
Tumor Lysis Syndrome | 2 | 2022 | 38 | 0.370 |
Why?
|
Middle Aged | 76 | 2025 | 223737 | 0.370 |
Why?
|
Quality of Life | 3 | 2023 | 13510 | 0.360 |
Why?
|
Molecular Targeted Therapy | 9 | 2024 | 2830 | 0.350 |
Why?
|
Immunotherapy | 6 | 2019 | 4756 | 0.350 |
Why?
|
Leukemia | 1 | 2018 | 1520 | 0.350 |
Why?
|
Bone Marrow | 10 | 2022 | 2936 | 0.340 |
Why?
|
Blood Proteins | 6 | 2016 | 1191 | 0.330 |
Why?
|
Signal Transduction | 26 | 2024 | 23653 | 0.320 |
Why?
|
Stromal Cells | 7 | 2022 | 1337 | 0.310 |
Why?
|
Cyclophosphamide | 5 | 2020 | 2227 | 0.310 |
Why?
|
Recurrence | 11 | 2024 | 8513 | 0.310 |
Why?
|
Leukocytosis | 1 | 2010 | 251 | 0.310 |
Why?
|
Disease-Free Survival | 12 | 2020 | 6856 | 0.300 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2013 | 1151 | 0.300 |
Why?
|
Cell Lineage | 2 | 2014 | 2576 | 0.300 |
Why?
|
Cell Movement | 10 | 2024 | 5216 | 0.290 |
Why?
|
MicroRNAs | 6 | 2024 | 3811 | 0.290 |
Why?
|
Survival Analysis | 12 | 2021 | 10115 | 0.280 |
Why?
|
Animals | 47 | 2024 | 169335 | 0.280 |
Why?
|
DNA Mutational Analysis | 10 | 2024 | 4124 | 0.280 |
Why?
|
Genomics | 5 | 2022 | 5928 | 0.280 |
Why?
|
Proto-Oncogene Proteins | 6 | 2024 | 4528 | 0.280 |
Why?
|
Mice, Transgenic | 14 | 2024 | 9565 | 0.270 |
Why?
|
Disease Progression | 19 | 2024 | 13674 | 0.270 |
Why?
|
Mice | 32 | 2024 | 82072 | 0.270 |
Why?
|
Immunoglobulin M | 5 | 2022 | 1528 | 0.260 |
Why?
|
Congresses as Topic | 2 | 2023 | 812 | 0.260 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 6 | 2019 | 111 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3118 | 0.250 |
Why?
|
Neoplasm Staging | 8 | 2020 | 11262 | 0.250 |
Why?
|
Burkitt Lymphoma | 4 | 2001 | 338 | 0.250 |
Why?
|
Neoplasm Proteins | 6 | 2015 | 3608 | 0.250 |
Why?
|
Receptors, Chemokine | 3 | 2003 | 652 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3241 | 0.250 |
Why?
|
Treatment Outcome | 25 | 2025 | 65480 | 0.250 |
Why?
|
Immunoglobulin lambda-Chains | 2 | 2020 | 83 | 0.250 |
Why?
|
Chemotaxis, Leukocyte | 4 | 2016 | 660 | 0.250 |
Why?
|
MAP Kinase Signaling System | 4 | 2022 | 1495 | 0.240 |
Why?
|
Toll-Like Receptor 9 | 2 | 2017 | 199 | 0.240 |
Why?
|
Immunoglobulin Light Chains | 5 | 2017 | 289 | 0.230 |
Why?
|
Adult | 48 | 2025 | 223851 | 0.230 |
Why?
|
Italy | 5 | 2024 | 856 | 0.230 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 627 | 0.230 |
Why?
|
Lymphocyte Activation | 13 | 2021 | 5505 | 0.230 |
Why?
|
ADP-ribosyl Cyclase | 2 | 2005 | 38 | 0.230 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2021 | 4413 | 0.230 |
Why?
|
Spliceosomes | 1 | 2024 | 116 | 0.230 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2020 | 1376 | 0.230 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2020 | 618 | 0.220 |
Why?
|
Mutagenesis, Insertional | 1 | 2006 | 662 | 0.220 |
Why?
|
Gene Deletion | 3 | 2015 | 2674 | 0.220 |
Why?
|
Survival Rate | 11 | 2021 | 12873 | 0.220 |
Why?
|
Receptors, Interleukin-1 | 2 | 2017 | 260 | 0.220 |
Why?
|
Autoantigens | 3 | 2017 | 891 | 0.210 |
Why?
|
Disease Models, Animal | 8 | 2022 | 18354 | 0.210 |
Why?
|
Receptor Cross-Talk | 1 | 2003 | 118 | 0.210 |
Why?
|
Sequoia | 1 | 2022 | 6 | 0.210 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 1437 | 0.210 |
Why?
|
Tumor Cells, Cultured | 11 | 2021 | 6131 | 0.210 |
Why?
|
Kv1.3 Potassium Channel | 1 | 2022 | 8 | 0.200 |
Why?
|
Genes, bcl-2 | 2 | 2003 | 119 | 0.200 |
Why?
|
Chemokines | 3 | 2021 | 963 | 0.200 |
Why?
|
Myeloid Differentiation Factor 88 | 5 | 2022 | 582 | 0.200 |
Why?
|
Tumor Suppressor Proteins | 4 | 2024 | 2812 | 0.200 |
Why?
|
Clinical Trials as Topic | 5 | 2024 | 8055 | 0.200 |
Why?
|
Dromaiidae | 1 | 2021 | 7 | 0.190 |
Why?
|
CD40 Ligand | 6 | 2021 | 528 | 0.190 |
Why?
|
Chemokines, CXC | 2 | 2003 | 420 | 0.190 |
Why?
|
Drug Synergism | 3 | 2020 | 1762 | 0.190 |
Why?
|
Phosphoproteins | 3 | 2024 | 2452 | 0.190 |
Why?
|
Follow-Up Studies | 14 | 2022 | 39394 | 0.190 |
Why?
|
Antigens, CD20 | 1 | 2022 | 199 | 0.190 |
Why?
|
Disease Susceptibility | 2 | 2018 | 1794 | 0.190 |
Why?
|
Hepatitis C, Chronic | 1 | 2010 | 1033 | 0.190 |
Why?
|
Genetic Predisposition to Disease | 7 | 2020 | 18068 | 0.190 |
Why?
|
Immunotherapy, Adoptive | 4 | 2022 | 1520 | 0.190 |
Why?
|
Amino Acid Sequence | 13 | 2018 | 13427 | 0.190 |
Why?
|
Hemorrhage | 7 | 2023 | 3466 | 0.180 |
Why?
|
Genes, T-Cell Receptor | 1 | 2020 | 29 | 0.180 |
Why?
|
Cell Proliferation | 6 | 2024 | 10486 | 0.180 |
Why?
|
RNA, Messenger | 7 | 2022 | 12806 | 0.180 |
Why?
|
Cell Communication | 4 | 2016 | 1660 | 0.180 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2020 | 23 | 0.180 |
Why?
|
Isoquinolines | 2 | 2020 | 354 | 0.180 |
Why?
|
Tosyl Compounds | 1 | 2020 | 115 | 0.170 |
Why?
|
Immunological Synapses | 1 | 2020 | 58 | 0.170 |
Why?
|
Vaccines, Subunit | 1 | 2020 | 159 | 0.170 |
Why?
|
Extracellular Space | 1 | 2002 | 565 | 0.170 |
Why?
|
Atrial Fibrillation | 5 | 2023 | 5176 | 0.170 |
Why?
|
Leukemia, Myeloid | 1 | 2003 | 693 | 0.170 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2024 | 633 | 0.170 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 3 | 2015 | 69 | 0.170 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2020 | 75 | 0.170 |
Why?
|
Tretinoin | 2 | 2018 | 525 | 0.170 |
Why?
|
DNA Methylation | 4 | 2019 | 4432 | 0.170 |
Why?
|
Spleen | 5 | 2022 | 2294 | 0.170 |
Why?
|
T-Lymphocyte Subsets | 1 | 2007 | 1813 | 0.160 |
Why?
|
Immunoglobulin D | 2 | 2016 | 55 | 0.160 |
Why?
|
Diagnosis, Differential | 7 | 2018 | 13021 | 0.160 |
Why?
|
Phenotype | 11 | 2022 | 16731 | 0.160 |
Why?
|
Liver Cirrhosis | 1 | 2010 | 1962 | 0.160 |
Why?
|
Aspergillus fumigatus | 1 | 2020 | 158 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2020 | 3621 | 0.160 |
Why?
|
Autoimmunity | 1 | 2007 | 1360 | 0.160 |
Why?
|
Ecosystem | 1 | 2023 | 494 | 0.160 |
Why?
|
Salvage Therapy | 4 | 2020 | 1277 | 0.160 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2019 | 77 | 0.160 |
Why?
|
Taiwan | 2 | 2017 | 524 | 0.160 |
Why?
|
Cell Survival | 10 | 2021 | 5793 | 0.160 |
Why?
|
Hereditary Angioedema Types I and II | 1 | 2018 | 10 | 0.160 |
Why?
|
Antigens, CD | 6 | 2012 | 4032 | 0.160 |
Why?
|
DNA-Binding Proteins | 6 | 2015 | 9618 | 0.150 |
Why?
|
Aspergillosis | 1 | 2020 | 242 | 0.150 |
Why?
|
Immunoglobulin Class Switching | 2 | 2019 | 289 | 0.150 |
Why?
|
Immunoglobulin Isotypes | 1 | 2018 | 158 | 0.150 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1060 | 0.150 |
Why?
|
Cytogenetic Analysis | 2 | 2016 | 271 | 0.150 |
Why?
|
Cytogenetics | 1 | 2019 | 198 | 0.150 |
Why?
|
Leukocytes, Mononuclear | 4 | 2024 | 1855 | 0.150 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 3 | 2015 | 812 | 0.150 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2005 | 1803 | 0.150 |
Why?
|
Choice Behavior | 1 | 2024 | 848 | 0.150 |
Why?
|
Epigenomics | 2 | 2021 | 961 | 0.150 |
Why?
|
Disease Management | 4 | 2018 | 2537 | 0.150 |
Why?
|
Retrospective Studies | 13 | 2023 | 81903 | 0.150 |
Why?
|
Cell Line, Tumor | 13 | 2022 | 17173 | 0.150 |
Why?
|
Bone Marrow Cells | 4 | 2012 | 2414 | 0.150 |
Why?
|
Hepatitis B, Chronic | 1 | 2022 | 413 | 0.150 |
Why?
|
Antigens | 3 | 2023 | 1444 | 0.150 |
Why?
|
Neoplasm Transplantation | 4 | 2020 | 2018 | 0.140 |
Why?
|
Gene Rearrangement | 5 | 2021 | 1148 | 0.140 |
Why?
|
Translocation, Genetic | 4 | 2016 | 1395 | 0.140 |
Why?
|
Anilides | 1 | 2020 | 414 | 0.140 |
Why?
|
Cells, Cultured | 11 | 2017 | 19023 | 0.140 |
Why?
|
Indolizines | 1 | 2017 | 30 | 0.140 |
Why?
|
Chemokine CCL22 | 3 | 2002 | 27 | 0.140 |
Why?
|
Cyclic N-Oxides | 1 | 2017 | 72 | 0.140 |
Why?
|
Macrophages | 3 | 2020 | 5801 | 0.140 |
Why?
|
Cell Culture Techniques | 2 | 2022 | 1667 | 0.140 |
Why?
|
Coculture Techniques | 6 | 2021 | 1342 | 0.140 |
Why?
|
Preleukemia | 3 | 2010 | 34 | 0.140 |
Why?
|
Aging | 2 | 2007 | 8745 | 0.140 |
Why?
|
Receptor, IGF Type 1 | 1 | 2019 | 384 | 0.140 |
Why?
|
Chromogranin A | 1 | 2016 | 47 | 0.140 |
Why?
|
Immunologic Surveillance | 1 | 2017 | 93 | 0.140 |
Why?
|
Camptothecin | 1 | 2020 | 600 | 0.130 |
Why?
|
Calreticulin | 1 | 2017 | 115 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2007 | 4651 | 0.130 |
Why?
|
Receptors, Notch | 1 | 2021 | 751 | 0.130 |
Why?
|
Cysteine | 1 | 2021 | 897 | 0.130 |
Why?
|
Cytidine Deaminase | 2 | 2015 | 249 | 0.130 |
Why?
|
Base Sequence | 4 | 2018 | 12430 | 0.130 |
Why?
|
Adoptive Transfer | 1 | 2018 | 824 | 0.130 |
Why?
|
Consensus | 3 | 2022 | 3214 | 0.130 |
Why?
|
Binding, Competitive | 1 | 2017 | 1142 | 0.120 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 115 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2024 | 10400 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.120 |
Why?
|
Gene Expression Profiling | 9 | 2019 | 9549 | 0.120 |
Why?
|
Azacitidine | 1 | 2017 | 336 | 0.120 |
Why?
|
Nitriles | 1 | 2020 | 990 | 0.120 |
Why?
|
Hypertension | 4 | 2023 | 8617 | 0.120 |
Why?
|
Chromosomes, Human, Pair 13 | 2 | 2014 | 192 | 0.120 |
Why?
|
Adaptor Proteins, Signal Transducing | 7 | 2017 | 2911 | 0.120 |
Why?
|
Nitrogen Mustard Compounds | 1 | 2014 | 44 | 0.120 |
Why?
|
Mice, Inbred BALB C | 3 | 2014 | 6232 | 0.120 |
Why?
|
Drug Therapy | 1 | 2017 | 504 | 0.120 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2014 | 283 | 0.120 |
Why?
|
Gene Frequency | 6 | 2021 | 3626 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1197 | 0.120 |
Why?
|
Multigene Family | 3 | 2024 | 1082 | 0.110 |
Why?
|
Receptors, Antigen | 1 | 2014 | 51 | 0.110 |
Why?
|
Blotting, Western | 3 | 2017 | 5033 | 0.110 |
Why?
|
DNA, Antisense | 1 | 2013 | 44 | 0.110 |
Why?
|
Toll-Like Receptor 2 | 1 | 2016 | 348 | 0.110 |
Why?
|
I-kappa B Kinase | 1 | 2015 | 250 | 0.110 |
Why?
|
Diarrhea | 5 | 2019 | 1320 | 0.110 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 318 | 0.110 |
Why?
|
Thionucleotides | 1 | 2013 | 107 | 0.110 |
Why?
|
Monocytes | 1 | 2003 | 2603 | 0.110 |
Why?
|
Sweden | 1 | 2016 | 1382 | 0.110 |
Why?
|
Ribosomal Proteins | 1 | 2015 | 370 | 0.110 |
Why?
|
Age Factors | 3 | 2020 | 18435 | 0.110 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2041 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 647 | 0.110 |
Why?
|
Mice, Knockout | 6 | 2016 | 14484 | 0.110 |
Why?
|
Membrane Glycoproteins | 6 | 2012 | 3713 | 0.100 |
Why?
|
Remission Induction | 3 | 2015 | 2408 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15951 | 0.100 |
Why?
|
Molecular Sequence Data | 8 | 2014 | 17629 | 0.100 |
Why?
|
Toll-Like Receptor 7 | 1 | 2014 | 169 | 0.100 |
Why?
|
Gene Expression | 7 | 2021 | 7603 | 0.100 |
Why?
|
Polymerase Chain Reaction | 4 | 2012 | 6086 | 0.100 |
Why?
|
Cladribine | 1 | 2012 | 34 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2016 | 2433 | 0.100 |
Why?
|
Models, Biological | 6 | 2015 | 9499 | 0.100 |
Why?
|
Alleles | 4 | 2016 | 6901 | 0.100 |
Why?
|
Biomimetics | 1 | 2013 | 172 | 0.100 |
Why?
|
Chemokine CCL17 | 2 | 2002 | 26 | 0.100 |
Why?
|
Thalidomide | 1 | 2017 | 886 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2014 | 362 | 0.100 |
Why?
|
Epigenesis, Genetic | 3 | 2021 | 3836 | 0.100 |
Why?
|
Gene Targeting | 1 | 2015 | 841 | 0.100 |
Why?
|
Cohort Studies | 11 | 2021 | 41808 | 0.100 |
Why?
|
Nuclear Proteins | 3 | 2017 | 5804 | 0.100 |
Why?
|
Cytoskeleton | 3 | 2014 | 1179 | 0.100 |
Why?
|
Iron | 1 | 2020 | 1814 | 0.100 |
Why?
|
Receptors, IgE | 2 | 2011 | 375 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7460 | 0.100 |
Why?
|
Genes, p53 | 1 | 2014 | 716 | 0.100 |
Why?
|
Flavonoids | 1 | 2015 | 447 | 0.100 |
Why?
|
Blood Donors | 1 | 2013 | 344 | 0.100 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1421 | 0.090 |
Why?
|
Protein Binding | 3 | 2017 | 9344 | 0.090 |
Why?
|
bcl-2-Associated X Protein | 2 | 2005 | 282 | 0.090 |
Why?
|
Risk Factors | 7 | 2022 | 74976 | 0.090 |
Why?
|
Down-Regulation | 2 | 2019 | 2942 | 0.090 |
Why?
|
Lymphocytes | 2 | 2012 | 2614 | 0.090 |
Why?
|
Hedgehog Proteins | 1 | 2015 | 771 | 0.090 |
Why?
|
Chemokine CXCL13 | 2 | 2018 | 62 | 0.090 |
Why?
|
Lymphoproliferative Disorders | 1 | 2014 | 529 | 0.090 |
Why?
|
Genetic Association Studies | 2 | 2017 | 2748 | 0.090 |
Why?
|
Neutropenia | 3 | 2023 | 893 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3215 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8749 | 0.090 |
Why?
|
Mortality | 1 | 2021 | 2914 | 0.090 |
Why?
|
Ribonucleases | 1 | 2010 | 266 | 0.090 |
Why?
|
src-Family Kinases | 1 | 2013 | 539 | 0.090 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2011 | 432 | 0.090 |
Why?
|
Indoles | 2 | 2019 | 1836 | 0.080 |
Why?
|
Cell Differentiation | 5 | 2012 | 11684 | 0.080 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4785 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3438 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1881 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 317 | 0.080 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4862 | 0.080 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2018 | 5716 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2016 | 2893 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 1 | 2001 | 3408 | 0.080 |
Why?
|
Phosphorylation | 5 | 2014 | 8317 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6547 | 0.080 |
Why?
|
Chromosomes, Human | 1 | 2010 | 438 | 0.080 |
Why?
|
Thrombosis | 1 | 2022 | 2956 | 0.080 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2008 | 171 | 0.080 |
Why?
|
Chlamydophila psittaci | 1 | 2007 | 2 | 0.070 |
Why?
|
Canaries | 1 | 2007 | 6 | 0.070 |
Why?
|
Cell Death | 1 | 2013 | 1682 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2011 | 2848 | 0.070 |
Why?
|
Bird Diseases | 1 | 2007 | 20 | 0.070 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2007 | 70 | 0.070 |
Why?
|
Europe | 3 | 2020 | 3441 | 0.070 |
Why?
|
Chlamydophila Infections | 1 | 2007 | 23 | 0.070 |
Why?
|
Lymphoid Tissue | 1 | 2009 | 446 | 0.070 |
Why?
|
Software | 2 | 2021 | 4479 | 0.070 |
Why?
|
Societies, Medical | 1 | 2020 | 3968 | 0.070 |
Why?
|
Prevalence | 4 | 2019 | 15879 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2011 | 2525 | 0.070 |
Why?
|
Pyrroles | 1 | 2013 | 1125 | 0.070 |
Why?
|
Promoter Regions, Genetic | 2 | 2019 | 5801 | 0.070 |
Why?
|
Epitopes | 2 | 2011 | 2529 | 0.070 |
Why?
|
Bronchial Neoplasms | 1 | 2007 | 111 | 0.070 |
Why?
|
Lymphotoxin-alpha | 2 | 2012 | 94 | 0.070 |
Why?
|
Cell Adhesion | 4 | 2021 | 3102 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2012 | 620 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2019 | 4592 | 0.070 |
Why?
|
Immunoglobulin Switch Region | 1 | 2006 | 44 | 0.070 |
Why?
|
Cell Line | 5 | 2021 | 15604 | 0.070 |
Why?
|
Mice, Inbred C57BL | 8 | 2021 | 22379 | 0.070 |
Why?
|
Chromosomes, Human, Pair 18 | 2 | 2016 | 247 | 0.070 |
Why?
|
Chromosomes, Human, Pair 14 | 2 | 2016 | 286 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2015 | 2592 | 0.070 |
Why?
|
Jurkat Cells | 1 | 2008 | 739 | 0.070 |
Why?
|
Palliative Care | 1 | 2021 | 3644 | 0.070 |
Why?
|
Alternative Splicing | 2 | 2024 | 1105 | 0.070 |
Why?
|
Fatigue | 3 | 2019 | 1557 | 0.070 |
Why?
|
Transplantation, Heterologous | 2 | 2016 | 2395 | 0.060 |
Why?
|
NFATC Transcription Factors | 1 | 2008 | 393 | 0.060 |
Why?
|
Tumor Escape | 2 | 2021 | 372 | 0.060 |
Why?
|
Immunity, Innate | 2 | 2020 | 3080 | 0.060 |
Why?
|
Eye Neoplasms | 1 | 2007 | 306 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10592 | 0.060 |
Why?
|
Transcription Factors | 3 | 2024 | 12174 | 0.060 |
Why?
|
B-Lymphocyte Subsets | 2 | 2006 | 241 | 0.060 |
Why?
|
Lacrimal Apparatus | 1 | 2007 | 223 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 1 | 2018 | 4076 | 0.060 |
Why?
|
Nanoparticles | 1 | 2017 | 1989 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2016 | 16053 | 0.060 |
Why?
|
Mediterranean Region | 1 | 2004 | 47 | 0.060 |
Why?
|
Retreatment | 2 | 2018 | 600 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2875 | 0.060 |
Why?
|
Incidence | 4 | 2024 | 21547 | 0.060 |
Why?
|
Databases, Factual | 2 | 2024 | 8094 | 0.060 |
Why?
|
Oligodeoxyribonucleotides | 2 | 2017 | 706 | 0.060 |
Why?
|
Genes, bcl-1 | 1 | 2003 | 11 | 0.060 |
Why?
|
Models, Genetic | 1 | 2014 | 3449 | 0.060 |
Why?
|
Dendritic Cells, Follicular | 2 | 2002 | 50 | 0.060 |
Why?
|
Research Personnel | 1 | 2009 | 590 | 0.060 |
Why?
|
Pedigree | 2 | 2008 | 4545 | 0.060 |
Why?
|
Up-Regulation | 3 | 2022 | 4148 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2016 | 5151 | 0.050 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 906 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2012 | 2323 | 0.050 |
Why?
|
Drug Interactions | 2 | 2018 | 1418 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2006 | 2574 | 0.050 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2003 | 122 | 0.050 |
Why?
|
Chemokine CCL20 | 1 | 2003 | 64 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2019 | 3810 | 0.050 |
Why?
|
Receptors, CCR6 | 1 | 2003 | 73 | 0.050 |
Why?
|
Focal Adhesion Kinase 2 | 1 | 2023 | 87 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2019 | 12467 | 0.050 |
Why?
|
Stimulation, Chemical | 1 | 2002 | 305 | 0.050 |
Why?
|
Receptors, CXCR5 | 1 | 2002 | 88 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2004 | 354 | 0.050 |
Why?
|
Hepacivirus | 1 | 2010 | 1344 | 0.050 |
Why?
|
Switzerland | 1 | 2023 | 323 | 0.050 |
Why?
|
Lymphocyte Subsets | 1 | 2003 | 313 | 0.050 |
Why?
|
Neoplastic Stem Cells | 2 | 2002 | 1356 | 0.050 |
Why?
|
Semaphorins | 1 | 2002 | 96 | 0.050 |
Why?
|
Receptors, CCR4 | 1 | 2002 | 77 | 0.050 |
Why?
|
Lymphocyte Transfusion | 1 | 2003 | 232 | 0.050 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2022 | 89 | 0.050 |
Why?
|
Lymph Nodes | 3 | 2016 | 3473 | 0.050 |
Why?
|
Young Adult | 6 | 2024 | 60131 | 0.050 |
Why?
|
Death, Sudden | 1 | 2024 | 301 | 0.050 |
Why?
|
Models, Immunological | 1 | 2004 | 518 | 0.050 |
Why?
|
Receptors, Cytokine | 1 | 2002 | 258 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2013 | 4568 | 0.050 |
Why?
|
Time Factors | 6 | 2020 | 40261 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2020 | 4356 | 0.050 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2024 | 379 | 0.050 |
Why?
|
Receptors, Immunologic | 1 | 2007 | 1418 | 0.050 |
Why?
|
Repressor Proteins | 1 | 2012 | 2986 | 0.050 |
Why?
|
Interleukin-12 | 1 | 2003 | 577 | 0.050 |
Why?
|
Chemotactic Factors | 1 | 2001 | 197 | 0.050 |
Why?
|
Nod2 Signaling Adaptor Protein | 2 | 2012 | 86 | 0.040 |
Why?
|
Chemokine CCL2 | 1 | 2003 | 606 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 344 | 0.040 |
Why?
|
Glycosylation | 1 | 2023 | 1101 | 0.040 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2003 | 633 | 0.040 |
Why?
|
Virus Activation | 1 | 2022 | 324 | 0.040 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 42 | 0.040 |
Why?
|
Antigens, CD19 | 3 | 2011 | 446 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2021 | 278 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2021 | 4290 | 0.040 |
Why?
|
Models, Molecular | 2 | 2021 | 5404 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2460 | 0.040 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 1998 | 18 | 0.040 |
Why?
|
Aldehyde Oxidase | 1 | 2018 | 4 | 0.040 |
Why?
|
Cross-Linking Reagents | 1 | 2002 | 692 | 0.040 |
Why?
|
Smith-Magenis Syndrome | 1 | 2018 | 19 | 0.040 |
Why?
|
Metabolic Networks and Pathways | 1 | 2023 | 800 | 0.040 |
Why?
|
Interleukin-4 | 1 | 2002 | 1157 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2022 | 533 | 0.040 |
Why?
|
Carrier Proteins | 2 | 2004 | 4939 | 0.040 |
Why?
|
Embryonal Carcinoma Stem Cells | 1 | 1998 | 20 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2018 | 118 | 0.040 |
Why?
|
Advisory Committees | 1 | 2022 | 797 | 0.040 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2004 | 1363 | 0.040 |
Why?
|
Amino Acid Substitution | 2 | 2015 | 1742 | 0.040 |
Why?
|
Aptamers, Nucleotide | 1 | 2019 | 163 | 0.040 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2018 | 97 | 0.040 |
Why?
|
bcl-Associated Death Protein | 1 | 1998 | 102 | 0.040 |
Why?
|
Vesicular stomatitis Indiana virus | 1 | 2017 | 93 | 0.040 |
Why?
|
Gene Regulatory Networks | 2 | 2019 | 1752 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11230 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2019 | 365 | 0.040 |
Why?
|
Common Variable Immunodeficiency | 1 | 1998 | 100 | 0.040 |
Why?
|
Immunologic Memory | 1 | 2004 | 1378 | 0.040 |
Why?
|
Indazoles | 1 | 2019 | 306 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3238 | 0.040 |
Why?
|
Histones | 2 | 2019 | 2603 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2010 | 2336 | 0.030 |
Why?
|
Anticoagulants | 3 | 2022 | 4850 | 0.030 |
Why?
|
Creatinine | 1 | 2022 | 1917 | 0.030 |
Why?
|
Chemokine CCL3 | 1 | 2016 | 85 | 0.030 |
Why?
|
Chemokine CCL4 | 1 | 2016 | 127 | 0.030 |
Why?
|
Patient Preference | 1 | 2024 | 947 | 0.030 |
Why?
|
Immunoglobulin Joining Region | 1 | 2016 | 37 | 0.030 |
Why?
|
Chick Embryo | 1 | 1998 | 975 | 0.030 |
Why?
|
Databases, Protein | 1 | 2018 | 390 | 0.030 |
Why?
|
Polymorphism, Genetic | 2 | 2017 | 4251 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 549 | 0.030 |
Why?
|
Antigens, CD1d | 1 | 2017 | 225 | 0.030 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 1560 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2021 | 1952 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2021 | 22296 | 0.030 |
Why?
|
World Health Organization | 1 | 2022 | 1328 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2018 | 527 | 0.030 |
Why?
|
bcl-X Protein | 1 | 1998 | 412 | 0.030 |
Why?
|
Automation | 1 | 2018 | 589 | 0.030 |
Why?
|
Clodronic Acid | 1 | 2016 | 60 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 190 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2017 | 400 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2024 | 1568 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2001 | 1252 | 0.030 |
Why?
|
Dimerization | 1 | 2017 | 886 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 878 | 0.030 |
Why?
|
Hydrogels | 1 | 2021 | 745 | 0.030 |
Why?
|
Adolescent | 5 | 2014 | 89244 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 20 | 0.030 |
Why?
|
Focus Groups | 1 | 2021 | 1462 | 0.030 |
Why?
|
Dendritic Cells | 2 | 2004 | 2748 | 0.030 |
Why?
|
Actins | 2 | 2014 | 2065 | 0.030 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2017 | 394 | 0.030 |
Why?
|
Mice, Inbred NZB | 1 | 2014 | 57 | 0.030 |
Why?
|
Receptor, Notch2 | 1 | 2015 | 90 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2012 | 2732 | 0.030 |
Why?
|
Drug Eruptions | 1 | 2018 | 335 | 0.030 |
Why?
|
Phagocytosis | 1 | 2020 | 1530 | 0.030 |
Why?
|
Point Mutation | 1 | 2020 | 1596 | 0.030 |
Why?
|
Safety | 1 | 2019 | 1161 | 0.030 |
Why?
|
Multicenter Studies as Topic | 2 | 2010 | 1737 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2017 | 11116 | 0.030 |
Why?
|
DNA Primers | 1 | 1999 | 2827 | 0.030 |
Why?
|
Tissue Scaffolds | 1 | 2021 | 951 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2024 | 2258 | 0.030 |
Why?
|
Aminoquinolines | 1 | 2014 | 105 | 0.030 |
Why?
|
DNA Replication | 1 | 2021 | 1428 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20245 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4363 | 0.030 |
Why?
|
Chromosomes, Mammalian | 1 | 2014 | 148 | 0.030 |
Why?
|
Ligands | 2 | 2012 | 3283 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 819 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2010 | 4919 | 0.030 |
Why?
|
Arthralgia | 1 | 2018 | 459 | 0.030 |
Why?
|
Immunogenetic Phenomena | 1 | 2013 | 23 | 0.030 |
Why?
|
Caspase 8 | 1 | 2014 | 198 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22389 | 0.030 |
Why?
|
Immunoglobulin gamma-Chains | 1 | 2013 | 33 | 0.030 |
Why?
|
Methylation | 1 | 2016 | 1078 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2108 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2015 | 874 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2015 | 393 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 54962 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2015 | 930 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2002 | 2820 | 0.030 |
Why?
|
Exanthema | 1 | 2018 | 503 | 0.030 |
Why?
|
Mass Screening | 1 | 2009 | 5457 | 0.030 |
Why?
|
Tumor Burden | 1 | 2019 | 1913 | 0.030 |
Why?
|
Leukemic Infiltration | 1 | 2012 | 47 | 0.030 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 505 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 687 | 0.030 |
Why?
|
Transfection | 2 | 2015 | 5763 | 0.030 |
Why?
|
Acute Disease | 1 | 2003 | 7245 | 0.030 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2015 | 507 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2014 | 1379 | 0.020 |
Why?
|
Liposomes | 1 | 2016 | 793 | 0.020 |
Why?
|
Pilot Projects | 2 | 2018 | 8748 | 0.020 |
Why?
|
Receptor, Notch1 | 1 | 2014 | 520 | 0.020 |
Why?
|
Health Expenditures | 1 | 2024 | 2396 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4428 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2014 | 737 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 552 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 440 | 0.020 |
Why?
|
Cytoplasm | 1 | 2015 | 1505 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2022 | 2542 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2014 | 2179 | 0.020 |
Why?
|
Cell Separation | 1 | 2015 | 1728 | 0.020 |
Why?
|
Telomere | 1 | 2016 | 943 | 0.020 |
Why?
|
Colitis | 1 | 2018 | 1242 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2002 | 4413 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1997 | 1384 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3070 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1517 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3433 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 2016 | 1601 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 693 | 0.020 |
Why?
|
Autophagy | 1 | 2017 | 1351 | 0.020 |
Why?
|
Calcium | 1 | 2022 | 5792 | 0.020 |
Why?
|
Luminescent Proteins | 1 | 2012 | 839 | 0.020 |
Why?
|
Cell Shape | 1 | 2010 | 371 | 0.020 |
Why?
|
Nod1 Signaling Adaptor Protein | 1 | 2008 | 12 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2012 | 755 | 0.020 |
Why?
|
RNA | 1 | 2019 | 2727 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2014 | 999 | 0.020 |
Why?
|
Genetic Markers | 1 | 2015 | 2604 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2019 | 3726 | 0.020 |
Why?
|
Lipopeptides | 1 | 2008 | 71 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2664 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2004 | 3626 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2015 | 1758 | 0.020 |
Why?
|
Binding Sites, Antibody | 1 | 2008 | 340 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 2089 | 0.020 |
Why?
|
United States | 3 | 2021 | 73186 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2016 | 4835 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6805 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4456 | 0.020 |
Why?
|
Headache | 1 | 2015 | 1264 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 4040 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2164 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9621 | 0.020 |
Why?
|
Antibody Formation | 1 | 2012 | 1393 | 0.020 |
Why?
|
Ultrasonography | 1 | 2020 | 6002 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 1748 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2011 | 1356 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 2 | 2011 | 3744 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8384 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3588 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2004 | 1658 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2010 | 1904 | 0.020 |
Why?
|
Peptidoglycan | 1 | 2008 | 246 | 0.020 |
Why?
|
Cytokines | 3 | 2011 | 7453 | 0.020 |
Why?
|
Sequence Homology | 1 | 2006 | 199 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 11932 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2015 | 2885 | 0.020 |
Why?
|
Antigen-Antibody Reactions | 1 | 2006 | 342 | 0.020 |
Why?
|
Greece | 1 | 2006 | 340 | 0.020 |
Why?
|
Rheumatoid Factor | 1 | 2006 | 185 | 0.020 |
Why?
|
Medication Adherence | 1 | 2018 | 2192 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2018 | 2763 | 0.020 |
Why?
|
Oligonucleotides | 1 | 2008 | 563 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2474 | 0.020 |
Why?
|
Doxycycline | 1 | 2007 | 349 | 0.020 |
Why?
|
Thiazoles | 1 | 2013 | 1542 | 0.020 |
Why?
|
France | 1 | 2006 | 497 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2005 | 223 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 208 | 0.020 |
Why?
|
Spain | 1 | 2006 | 485 | 0.020 |
Why?
|
DNA | 1 | 2019 | 7214 | 0.020 |
Why?
|
Environmental Health | 1 | 2007 | 298 | 0.010 |
Why?
|
Mice, Nude | 1 | 2010 | 3631 | 0.010 |
Why?
|
Child, Preschool | 4 | 2016 | 42683 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2006 | 1065 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2011 | 1895 | 0.010 |
Why?
|
CpG Islands | 1 | 2008 | 1210 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2005 | 609 | 0.010 |
Why?
|
Cell Migration Inhibition | 1 | 2003 | 97 | 0.010 |
Why?
|
Gene Silencing | 1 | 2010 | 1505 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8559 | 0.010 |
Why?
|
Chemokine CXCL9 | 1 | 2003 | 135 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10765 | 0.010 |
Why?
|
Graft vs Tumor Effect | 1 | 2003 | 68 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14794 | 0.010 |
Why?
|
Antigens, Bacterial | 1 | 2008 | 1150 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 2004 | 472 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2018 | 3447 | 0.010 |
Why?
|
Interferon-gamma | 2 | 2004 | 3163 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2014 | 2100 | 0.010 |
Why?
|
Basement Membrane | 1 | 2003 | 348 | 0.010 |
Why?
|
Chemokine CXCL10 | 1 | 2003 | 311 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6236 | 0.010 |
Why?
|
STAT1 Transcription Factor | 1 | 2003 | 343 | 0.010 |
Why?
|
Palatine Tonsil | 1 | 2002 | 193 | 0.010 |
Why?
|
Cell Cycle | 1 | 2010 | 2937 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12095 | 0.010 |
Why?
|
Amino Acids | 1 | 2007 | 1716 | 0.010 |
Why?
|
Proteomics | 1 | 2014 | 3914 | 0.010 |
Why?
|
Chromatin | 1 | 2012 | 2981 | 0.010 |
Why?
|
International Cooperation | 1 | 2006 | 1436 | 0.010 |
Why?
|
Blood Transfusion, Autologous | 1 | 1999 | 130 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2002 | 1990 | 0.010 |
Why?
|
Binding Sites | 1 | 2007 | 6023 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2012 | 3840 | 0.010 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2000 | 692 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 14201 | 0.010 |
Why?
|
Hemolysis | 1 | 1999 | 417 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2005 | 1966 | 0.010 |
Why?
|
Inflammation | 1 | 2017 | 10868 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2006 | 2211 | 0.010 |
Why?
|
Endothelium | 1 | 1999 | 768 | 0.010 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 1997 | 510 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1997 | 240 | 0.010 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2000 | 1133 | 0.010 |
Why?
|
Child | 3 | 2016 | 80960 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 13048 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2003 | 1739 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24333 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4478 | 0.010 |
Why?
|
CHO Cells | 1 | 1997 | 1379 | 0.010 |
Why?
|
Trans-Activators | 1 | 2003 | 2858 | 0.010 |
Why?
|
Cricetinae | 1 | 1997 | 2423 | 0.010 |
Why?
|
Liver | 1 | 2007 | 7578 | 0.010 |
Why?
|
Infant | 2 | 2005 | 36556 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2003 | 3048 | 0.010 |
Why?
|
Reference Values | 1 | 1997 | 4940 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2007 | 7478 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1999 | 26428 | 0.000 |
Why?
|